RXRX
Recursion Pharmaceuticals, Inc.Company with tickers: RXRX
CIK
1601830
CUSIP
75629V104
Shares Outstanding
524,677,865
13F Activity (30d)
194 filings
190 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $6,472,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $87,896,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Operating Income | $-128,505,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Net Income | $-117,504,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Basic) | $-0.22 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Diluted) | $-0.22 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |